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ABOUT THE TRENT INSTITUTE FOR HEALTH SERVICES RESEARCH 
 
The Trent Institute for Health Services Research is a collaborative venture between the 
Universities of Leicester, Nottingham and Sheffield with support from NHS Executive Trent.  
 
The Institute: 
 
x provides advice and support to NHS staff on undertaking Health Services Research 
(HSR); 
  
x provides a consultancy service to NHS bodies on service problems; 
  
x provides training in HSR for career researchers and for health service professionals; 
  
x provides educational support to NHS staff in the application of the results of research; 
  
x disseminates the results of research to influence the provision of health care. 
 
The Directors of the Institute are: Professor R L Akehurst (Sheffield); 
     Professor C E D Chilvers (Nottingham); and  
     Professor M Clarke (Leicester).  
Professor Akehurst currently undertakes the role of Institute Co-ordinator. 
 
A Core Unit, which provides central administrative and co-ordinating services, is located in 
Regent Court within the University of Sheffield in conjunction with the School of Health and 
Related Research (ScHARR). 
FOREWORD 
 
Individuals or small groups in each District Health Authority in Trent have historically 
considered evidence on the likely effectiveness of new procedures or therapies in 
conjunction with their cost, making judgements on whether these should be supported. 
Since all or most Health Authorities face the same issues, there tends to be repetition in 
analysis and this can be wasteful of scarce professional expertise. 
 
There are national attempts to remedy this situation by providing information on the 
effectiveness of interventions and these are welcomed. There remains, however, a 
significant gap between the results of research undertaken and their incorporation into 
contracts.  
 
Following a request from purchasers, a network has been established in the Trent Region to 
allow purchasers to share research knowledge about the effectiveness of acute service 
interventions and to determine collectively their purchasing stance. 
 
ScHARR, which houses the Sheffield Unit of the Trent Institute for Health Services 
Research, facilitates a Working Group on Acute Purchasing. A list of interventions for 
consideration is recommended by the purchasing authorities in Trent and approved by the 
Purchasing Authorities Chief Executives (PACE) and the Trent Development and Evaluation 
Committee (DEC). A public health consultant from a purchasing authority leads on each 
topic and is assisted, as necessary, by a support team from ScHARR which provides help 
including literature searching, health economics and modelling. A seminar is then led by the 
consultant on the particular intervention where purchasers and provider clinicians consider 
research evidence and agree provisional recommendations on purchasing policy. The 
guidance emanating from the seminars is reflected in this series of Guidance Notes. 
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EXECUTIVE SUMMARY 
 
Cochlear Implantation (CI) is a rapidly evolving health technology which restores useful 
forms of auditory sensation to people who are profoundly deaf, through electrical stimulation 
of the auditory nerve with electrodes implanted in the inner ear (the cochlea). The primary 
intention is to reduce disability and to improve the quality of life by increasing the capacity 
for using spoken language. 
 
CI is suitable for two classes of client:  
(a) children and adults who lost their hearing after learning spoken language; and  
(b) young children who either lost their hearing before acquiring spoken language or who 
were born deaf.  
There are approximately 4,000 suitable candidates for CI in the UK. Current uptake patterns 
suggest that 1,600 will seek and receive CI. A district with a population of 0.5 million would 
expect up to one new post-lingually deafened client every two years, and two new pre-
lingually deafened clients per year. There would also be a backlog of up to 20 post-lingually 
deafened clients and up to 12 pre-lingually deafened clients. 
 
The discounted cost of implantation and long-term management is £36,400 for adults and 
£57,400 for children. The cost per QALY for CI is £13,300 (range £10,200 to £30,500).  
 
The cost effectiveness of CI is likely to be improved by ensuring that the intervention is 
provided by appropriately trained specialist teams, with sufficient workload to maintain their 
skills, operating in specialist centres. Patient selection should also be encouraged to ensure 
that CI is provided to those patients most likely to benefit. 
 
It is recommended that, for patients meeting the candidature criteria set out in this guidance, 
purchasers should agree funding for the provision of CI in specialist Cochlear Implantation 
Centres, within agreed guidelines governing candidature and with the assurance that the 
results of audit are reported. 
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1.  INTRODUCTION 
 
1.1 Cochlear Implantation : Incidence and Pathology 
 
Cochlear Implantation (CI) is a rapidly evolving health technology which restores useful 
forms of auditory sensation to people who are profoundly deaf, through electrical stimulation 
of the auditory nerve with electrodes implanted in the inner ear (the cochlea). The primary 
intention is to reduce disability and improve quality of life by increasing the capacity for using 
spoken language. CI was introduced to the NHS through a 4-year Government initiative 
(1990-1994) during which central funds partly underwrote the costs of provision by selected 
provider units. 
 
(i) Implant Systems 
 
Implant systems consist of external and internal components. Externally, a microphone, 
worn above the ear, is connected to a speech processor, typically carried on a belt or in a 
pocket, which in turn is linked to a transmitter coil placed on the outside of the head. The 
processor converts the signal from the microphone into a form suitable for radio-frequency 
transmission, through the scalp, to a receiver-stimulator package which is placed in a well 
fashioned surgically in the skull behind the ear. The receiver-stimulator decodes the radio-
frequency signal and converts it into electrical pulses which are sent to an array of 
electrodes implanted surgically in the inner ear.  
 
7KHSUHIHUUHG IRUPRI LPSODQW V\VWHP LV µPXOWL-FKDQQHO¶6XFKV\VWHPVGLYLGH WKHDFRXVWLF
signal into a set of discrete frequency bands. The pattern of energy in different bands is 
represented by the pattern of electrical stimulation on different members of the array of 
implanted electrodes. In this way, the normal mapping between acoustical frequency and 
place of stimulation in the cochlea is partly restored. 
 
(ii) Management of Patients 
 
Management of patients involves four phases:  
(a) pre-operative assessment and counselling, to determine suitability and to ensure 
informed consent to treatment;  
(b) surgery;  
(c) rehabilitation, including device tuning and speech/hearing therapy;  
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(d) long-term maintenance, to diagnose and remedy technical problems and, periodically,  to 
upgrade processors. 
 
(iii) Causes of Profound Deafness and Prospects for Prevention 
 
Profound deafness has many causes. It may be present at birth or develop at any point in 
life. Prospects for prevention during the next decade of more than a small proportion of 
cases are limited. It is estimated 1 that there are 150,000 people in the UK with profound 
hearing impairment (an average reduction of sensitivity of 95 decibels (dB) or more 
compared with normal hearing in the ear which has better hearing; a person with this degree 
RIKHDULQJORVVZRXOGEHFKDUDFWHULVHGDVKDYLQJDµKHDULQJOHYHO¶RIG% 
 
(iv) Candidates for CI 
 
CI is suitable for two classes of client:  
DFKLOGUHQDQGDGXOWVZKRORVWWKHLUKHDULQJDIWHUOHDUQLQJVSRNHQODQJXDJHµSRVW-OLQJXDOO\¶
deafened clients); and  
(b) young children who either lost their hearing before acquiring spoken language or who 
ZHUHERUQGHDIµSUH-OLQJXDOO\¶GHDIHQHGFOLHQWV 
 
1.1.1 Demand for CI 
 
(i) Post-lingually-deafened Children and Adults 
 
Candidature is defined by the intersection of :  
(a) profound deafness;  
(b) post-lingual acquisition;  
(c) an inability to obtain material benefit from acoustic hearing aids; 
(d) physical and intellectual fitness for surgery and rehabilitation; and  
(e) a strong commitment to treatment.   
The application of constraints (b)-(d) limits the number of candidates in the UK to 
approximately 4,000. Current patterns of uptake imply that 1,600 of them will seek and 
receive CI. 2 
 
(ii) Young Pre-lingually Deafened Children: 
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Candidature is defined by the intersection of: 
(a) profound deafness;  
(b) an inability to obtain material benefit from acoustic hearing aids; and  
(c) a strong commitment to treatment on the part of parents and teachers.  
Approximately 220 children are born with profound hearing loss each year in the UK. A 
further 80 lose  this degree of hearing by the age of five, primarily as a result of meningitis.3 
It is estimated that CI will be sought on behalf of a high proportion of this population and that 
as many as two thirds will be clinically suitable to receive the service. 
 
(iii) Uptake of Services to Date 
 
Approximately 800 adults and 600 children have received CI in the UK. Approximately 
15,000 people have received CI world-wide. 
 
(iv) Expected Demand 
 
Table 1 provides estimates of the demand for CI in the UK, developed from epidemiological 
data on the prevalence and incidence of profound deafness, and on the uptake of CI 
services. 2 
 
Table 1: Expected Demand for Cochlear Implantation in a District with a 
  Total Population of 0.5m 
 
CLIENT GROUP BACKLOG ANNUAL INCIDENCE 
Post-lingually deafened clients 
(children and adults). 
14 (range 11-20, minus cases 
already implanted) 
0.5 cases (i.e. 1 case every 2 
years) (range 0-2) 
Pre-lingually deafened clients 
(children 2-6 years) 
10 (range 7-12, minus cases 
already implanted) 
2 cases (range 0-4) 
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2. COCHLEAR IMPLANTATION : SUMMARY OF EVIDENCE OF 
 EFFECTIVENESS 
 
2.1 Evidence of Effectiveness for Adults 
 
Acquired profound deafness is a chronic condition for which CI is an elective treatment of 
last resort. As  candidature for CI is defined partly by the inability to benefit from alternative 
therapies, randomised controlled trials (RCTs) comparing CI with other therapies have not 
been conducted. Instead, repeated-measures, involving tests on the same patients before 
and after implantation, have been used. These show consistent evidence of benefit in terms 
of improved communication skills and increased quality of life. 
 
Table 2 summarises outcomes measured in the UK during the MRC evaluation of the 
National CI Programme.2 These data were obtained from adults (18 years and older) who 
could not understand speech without lip-reading using acoustic hearing aids. The outcomes 
were first measured 9 months after implantation and were maintained without change when 
re-measured 18 months after implantation. 
 
These levels of outcome were shown when patients were equipped with 2nd-generation 
implant systems. Similar levels have been shown elsewhere in the world by patients 
equipped with 2nd-generation systems. Higher levels are now reported from patients using 
3rd-generation systems. 
 
The single most important outcome from CI is continued use of the implant system, because 
patients have the option of ceasing to use the device if it brings no benefit. The asymptotic 
level of elective non-use, estimated by survival analysis 5 years after implantation, is 8%.2 
Thus, by this measure, the ratio of the number of patients benefiting to the number treated 
(0.92) is high in relation to many other treatments. 
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In addition to the outcomes listed in Table 2,  the family and friends of patients reported: 
x amelioration of major difficulties of communication in relationships; 
x less need to simplify messages; 
x less fatigue engendered in patients by the need to ensure that messages had been 
understood; 
x less need to assist patients to communicate with others; and 
x greater participation by patients in activities outside the home. 
 7 
Table 2: Outcomes from Cochlear Implantation for Post-lingually  
  Deafened Adults 2  
   
OUTCOME MEASURE % PATIENTS 
DISPLAYING 
OUTCOME 
COMMENTS 
 1. Suitable referral willing to proceed 
with treatment 
50% Sophisticated techniques for 
assessing candidature make 
improved accuracy of pre-
referral assessment unlikely. 
 2. Evidence of use 
   All day while awake 
   At least 10 hours per day 
   At least 4 hours per day 
 
50% 
80% 
90% 
 
Data from patients with multi-
channel devices. Lower rates of 
use recorded from patients with 
single-channel devices. 
 3. Evidence of non-use 
   2 years after implantation 
 
   5 years after implantation 
 
 
3-5% (multi-channel) 
 10% (single-channel) 
   8% (multi-channel) 
 
8% non-use rate at 5 years 
estimated by survival analysis to 
be the asymptotic rate of 
elective non-use. Half of patients 
who subsequently became non-
users were implanted early in 
the Programme. 
 4. Identified some common 
environmental sounds 
97% 25% of patients identified more 
than 75% of sounds correctly. 
 5. Identified more words correctly in 
sentences when using implant in 
combination with lip-reading than 
when lip-reading alone. 
95%  
 6. Greater benefit to lip-reading than 
achieved pre-operatively with 
acoustic hearing aid 
80-90% Data from sub-set of patients 
with sufficient residual hearing 
for pre-operative testing with 
hearing aid(s) to be feasible. 
 7. Identified some words correctly in 
sentences without lip-reading 
 
  
 
  
Demonstrated some understanding 
of questions posed over the 
telephone by an unfamiliar talker 
 
 
   
Improved quality and/or intelligibility 
of own speech 
50% 
 
 
 
 
 
35% 
 
 
 
 
 
70% 
Score of 10% correct or greater; 
15% of patients scored 50% or 
more correct. (>50% 
corresponds to useful ability to 
converse without lip-reading.) 
 
Score of 10% correct or greater; 
15% of patients scored more 
than 50% correct. (>50% correct 
corresponds to useful ability to 
converse using telephone.) 
 
Most of remaining 30% already 
produced speech of acceptable 
quality and/or intelligibility. 
 8. Tinnitus attenuated or eliminated 50% Two-thirds of implanted patients 
experienced tinnitus pre-
operatively; tinnitus was 
attenuated or eliminated in half 
of them. 
 9. Reduction in self-reported hearing 
handicap 
90% 
 
 
 
10. Improvement in quality of life 
measured retrospectively with 
Glasgow Benefit Inventory 
96% Average change in quality of life 
is greater than that reported by 
moderately impaired patients 
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managed with hearing aids. 
 
11. Positive change in health-related 
quality of life measured 
retrospectively with EuroQol visual-
analogue scales 
94% Average change +0.23 on scale 
where 1 and 0 correspond to 
best and worst imaginable 
states of health. 
12. Occupational status No change 40% were in paid employment 
pre- and post-operatively. 
13.  Satisfaction with job No change  
14. Extent of unpaid work No change  
15. Average no. of people on whom 
patients relied for help in 
overcoming problems of 
communication 
6    (pre-op) 
3.5 (post-op) 
Average amount of help 
required from each helper was 
also reduced. 
16. Medical/Surgical complications 
  a) Mortality 
 
 
    
  b) Major problem 
 
 
 
 
 
  
 
 
 
 
 
 
  c) Failure of implanted device 
 
 
  d) Revision surgery 
 
 
  e) Minor problem 
 
nil 
 
 
 
10% (adults) 
  7% (children) 
 
 
 
 
 
 
 
 
 
 
 
1.6% (adults) 
0.7% (children) 
 
4.3% (adults) 
2.2%  (children) 
 
25%   (adults and              
children) 
 
No. of operations monitored: 
244 (adults) 
136 (children) 
 
Including: damage to VIIth nerve 
causing facial paralysis; 
infection or necrosis of skin flap; 
cholesteatomas; mispositioning 
or movement of the electrode 
array. All treated successfully by 
revision surgery or medical 
management. Probability of 
complications declines steeply 
over first 10  patients managed 
by a surgeon. 
 
 
 
 
 
 
 
 
Overcome by medical 
management or by retuning or 
replacing processors. 
 
High rate of technical problems 
due to lack of robustness of 
external components, notably 
Nucleus processors and Ineraid 
percutaneous connectors. 
 
 
 
2.2 Evidence of Effectiveness for Children 
 
For this client group, the immediate goal is to provide access to sound; the medium and 
long-term goals are to enable the acquisition or retention of useful forms of spoken 
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language leading first, to improved scholastic attainment and, then, to enhanced social 
independence and quality of life in adulthood. 
 
An RCT, though theoretically desirable, would be of impractically long duration, and might 
now be considered unethical for clearly defined candidates. The most powerful research 
designs have involved longitudinal case-control comparisons of children with implants and 
children managed with hearing aids or tactile aids.4,5 These studies have shown that children 
selected for CI typically have hearing levels exceeding 110 dB. With implants, these children 
function better than children with the same hearing levels who are managed with hearing 
aids or tactile aids. They function about as well as less impaired children with hearing levels 
of 90-100 dB who are equipped with hearing aids. Such children generally make good use 
of hearing aids and develop useful forms of spoken language. The linkage encourages the 
belief that children with implants will go on to develop spoken language. 
 
Since 1991, paediatric CI in the UK has undergone radical changes in attitude and level of 
activity following the results of a trial in North America that led to the endorsement by the 
Food and Drug Administration of an implant system for use with children. The MRC 
Evaluation obtained observational data on initial outcomes from children implanted in the UK 
and reviewed the literature internationally, reaching the following conclusions: 
 
x Post-lingually deafened children: Good outcomes are generally obtained for children of all 
ages, provided that there is a strong commitment to CI by the child, family, and teachers; 
outcomes are particularly good when implantation occurs soon after the onset of 
profound deafness; evidence of speech understanding is often displayed within a few 
months of implantation. 
  
x Pre-lingually deafened children: Generally, there is evidence of  the ability to detect and 
distinguish environmental sounds within a few months of implantation; evidence of the 
perception and production of speech emerges slowly, often not until the implant has been 
used for 1-3 years. The best outcomes are displayed when children are implanted before 
the age of 5 years; disappointing outcomes are often reported when children are 
implanted after the age of 10-13 years. A strong  informed commitment to CI by 
family and teachers is essential. 
 
Table 3 summarises evidence on effectiveness of CI in young children. 
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2.3 Conclusion on Direction of Evidence and its Quality 
 
For post-lingually deafened adults and children, there is strong, statistically robust evidence 
of effectiveness for appropriately selected candidates. 
 
For pre-lingually deafened children, there is strong evidence of positive initial outcomes for 
appropriately selected candidates. It is not yet clear what levels of skills in spoken language 
will be attained, nor to what extent these will be translated into enhanced scholastic 
achievements. Thus, although initial outcomes are promising, further longitudinal 
evaluation of outcomes from implanting pre-lingually deafened children is necessary. 
Similar conclusions were reached by an NIH Consensus Development Conference. 6 
 11 
Table 3: Outcomes from Cochlear Implantation for Pre-lingually Deafened 
  Children 
                                                         
OUTCOME MEASURE % PATIENTS 
DISPLAYING 
OUTCOME 
COMMENTS 
   
 1. Evidence of use 
 
   Full time: t10 hours per day 
   Part time: 4-10 hours per day 
   Non-users  
 
 
 
 
87% 
10% 
  3% 
 
 
 
Data from Reference 2 obtained 
by surveying outcomes for ~130 
children implanted in the UK by 
January 1994. 
 
 2. Auditory and linguistic skills 
 
 2.1 Six months after CI 
   
  Ability to identify some 
environmental sounds. 
 
  Ability to discriminate among a 
limited set of simple speech 
sounds. 
 
 2.2 Two years after CI 
 
  Ability to understand simple 
phrases without lip-reading, 
provided that the talker is familiar 
and there is a strong constraining 
context. 
 
 2.3 Three years after CI 
 
  Ability to participate in conversation 
with a familiar talker without lip-
reading. 
 
 
 
 
 
 
70% 
 
 
50% 
 
 
 
 
 
50% 
 
 
 
 
 
 
 
50% 
 
Data from Reference 2 
 
(i) Best outcomes are obtained 
for children implanted before the 
age of 5 years. 
 
(ii) Disappointing outcomes 
often reported if implantation 
occurs after the age of 10-13 
years. 
 
(iii) Strong informed 
commitment to CI from family 
and teachers essential. 
 
 3. Medical/surgical complications 
 
No more frequent than 
adults 
 
See Section in Table 2. 
 
 4. Pre-verbal communicative 
behaviour. 
 
 5. Speech perception. 
 
Similar to that of less 
impaired children 
managed with hearing 
aids who went on to 
develop useful forms 
of spoken language. 
 
Data from Reference 4 
 
 
Data from Reference 5 
 12 
3. COST AND BENEFIT IMPLICATIONS OF ADOPTING INTERVENTION 
 
CI is a new health technology which does not replace a previous or alternative intervention.  
The costs of CI are, therefore, true additional costs. Savings are most likely to occur within 
the budgets of education and social services as a result of reduced dependency on special 
education, on special equipment for daily living, and on social support in adulthood. 
 
3.1 Costs of Providing Cochlear Implantation 
 
The MRC evaluation measured the costs of providing CI and estimated the future costs, 
listed in Table 4 (inflated to 1996 price levels). Costs of provision to adult clients were 
averaged over nine service providers. Costs of provision to children were measured in a 
single hospital and may not be representative of the cost of providing paediatric implantation 
generally. The costs of long-term management are listed twice, first with future costs 
discounted to present price levels at 6% per annum, and second with future costs not 
discounted. All sums in Table 4 include the cost of the implant system (£13,000). 
 
Table 4: Costs of Cochlear Implantation and Long-term Management (1996 
  price levels) 
 
TIME-PERIOD ADULTS CHILDREN 
Assessment, implantation, 
rehabilitation in first year 
£23,600 £27,300 
Assessment, implantation, 
rehabilitation, and maintenance for 
a total of 12 years 
£31,800 (future costs discounted) 
£33,000 (future costs not 
discounted) 
£47,900 (future costs 
discounted) 
£53,000 (future costs not 
discounted) 
Assessment, implantation, 
rehabilitation, and maintenance 
over life-time 
£36,400 (future costs discounted) 
£49,700 (future costs not 
discounted) 
£57,400 (future costs 
discounted) 
£119,600 (future costs not 
discounted) 
 
 
Current charges for CI services by providers in Trent Region, or within easy access from 
Trent, are given in Tables 6 and 7 
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3.2 Cost-utility 
 
The MRC evaluation estimated the cost-utility of CI for post-lingually deafened adults. 
Sensitivity analysis was used to set plausible limits on the range of estimates. Given that the 
average age at the time of implantation in the UK has been 49 years, future costs and 
benefits were aggregated over an expected further life-time of 26 years. Future costs were 
discounted to present price levels at 6% per annum. The results, inflated to 1996 price 
levels, are: 
x £13,300 per QALY (range £10,200 - £30,500) if future benefits are discounted at 6% per 
annum. 
x £6,600 per QALY (range £5,100 - £15,300) if future benefits are not discounted. 
According to these estimates, the cost-utility of CI falls in the middle of the range of 
frequently quoted estimates for therapies in the UK (Table 5) and represents acceptable 
value for money. 
 
These calculations were based on measurements made during the introduction of CI to the 
NHS. Technical improvements in implant systems leading to better outcomes, and increases 
in the efficiency of patient management, should improve cost-effectiveness. Further 
research is required to establish whether the expected changes occur. 
 
Table 5: Cost/QALY of Cochlear Implantation and Other Therapies 
 
THERAPY COST/QALY 
(£ 1996) 
Pacemaker insertion 1,300 
Renal transplantation 5,700 
Heart transplantation 9,500 
Cochlear Implantation (adult) 13,300 
Home haemodialysis 21,000 
Hospital haemodialysis 26,700 
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Table 6: Charges for Adult Cochlear Implantation set by Hospitals in Trent 
  or within Easy Reach of Trent 
  
PROVIDER CHARGES (£) 
 
Assessment Implantation 
+ 1st Year  
Years 2-3 
(price / 
year) 
Year 4+ Do follow 
up costs 
cover 
upgrades? 
Total at 5 
years (not 
discounted) 
Total at 12 
years (not 
discounted) 
4XHHQ¶V0HGLFDO
Centre, 
Nottingham 
1996/97 
1995/96 
 
 
 
1,500 
3,000 
 
 
 
24,500 
24,500 
 
 
 
1,350 
1,350 
 
 
 
1,350 
1,350 
 
 
 
Yes 
Yes 
 
 
 
31,400 
32,900 
 
 
 
40,850 
42,350 
University 
Hospital, 
Birmingham 
(formerly QEH) 
 
 
483 
 
24,584 
 
1,416 
 
1,416 
 
Yes 
 
30,731 
 
40,643 
Addenbrookes, 
Cambridge 
 
1,215 
 
22,860 
 
1,700 
 
1,700 
 
Yes 
 
30,875 
 
42,775 
 
Royal Infirmary, 
Bradford 
 
 
670 
 
25,142 
+ 227 yr 1 
 
1,339 
 
 
1,159 
 
Yes 
 
31,035 
 
39,148 
Royal Infirmary, 
Manchester 
 
 
448 
 
28,038 
 
1,402 
 
1,402 
 
Yes 
 
34,094 
 
43,908 
Royal Hallamshire, 
Sheffield 
 
250 
 
27,500 
 
1,500 
 
1,200 
 
No 
 
33,150 
 
41,550 
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Table 7: Charges for Paediatric Cochlear Implantation Set by Hospitals in 
  Trent or within Easy Reach of Trent 
 
PROVIDER CHARGES (£) 
 Assessment Implantation 
+ 1st Year  
Years 2-3 
(price / 
year) 
Year 4+ Do follow 
up costs 
cover 
upgrades? 
Total at 5 
years 
(not 
discounted) 
Total at 12 
years  
(not 
discounted) 
Queens Medical 
Centre, 
Nottingham 
1,115 27,000 
(includes 
assessment
) 
4,250 
(covers 
both 
years) 
2,000 Yes 35,250 49,250 
&KLOGUHQ¶V
Hospital, 
Birmingham 
1,585 26,476  
(includes 
assessment
) 
+2,660 yr 1 
1,860 1,860 Yes 36,576 49,596 
Addenbrookes, 
Cambridge 
1,215 29,200 
(includes 
assessment
) 
1,700 1,700 Yes 36,000 47,900 
Royal Infirmary, 
Bradford 
 
824 25,142 
(excludes 
assessment
) 
+490 yr 1 
2,307 (yr 
2) 
2,153 (yr 
3) 
1,993 Yes 34,902 48,853 
Royal Infirmary, 
Manchester 
 
448 30,734 1,225 1,225 Unknown 36,082 44,657 
 
3.3 Sustaining and Improving Cost-effectiveness 
 
The following are the key considerations in sustaining and improving the cost-effectiveness 
of CI services. 
 
3.3.1 Professional Composition of CI Teams 
 
A multi-disciplinary team is required with training and experience appropriate to the age 
group of clients to whom services will be directed. Team members should have received 
specific training in their roles as specified by Summerfield and Marshall.2  The size of a team 
should reflect its caseload. Teams should include: 
x medical/surgical skills from an ENT surgeon with established interests in neuro-otology; 
x scientific/technical skills from medical physicists or clinical audiologists; 
x rehabilitative skills from professionals with experience in speech therapy, hearing 
therapy, and/or the teaching of deaf children; 
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x a programme co-ordinator from one of the above grades to whom the lead surgeon 
delegates responsibility for the day-to-day management of the programme. 
In addition, access to a clinical psychologist is advisable.  
 
3.3.2 Choice of Impant Systems 
 
Modern multi-channel devices are strongly preferred. Devices should be of proven reliability 
and should be familiar to implant teams in order to minimise complication rates in surgery, 
failure rates of implanted components, time spent tuning, and time spent diagnosing 
problems. In choosing devices, teams should: 
x obtain evidence of effectiveness and reliability from manufacturers and from the clinical 
scientific literature; 
x obtain assurance of long-term support from manufacturers; 
x select devices that have been awarded the CE mark of the European Union; 
x develop a high level of expertise with each device they provide. 
 
3.3.3 Maintaining Skills 
 
Consensus of opinion suggests that at least 12 new adult and/or child cases are 
required per CI centre per year for viability. The incidence of medical/surgical 
complications falls with increasing experience of surgeons. There is no absolute number 
recommended to maintain skills. 
 
3.3.4 Siting of CI Centres 
 
CI is a low-volume treatment. A sustained throughput of patients is required to ensure the 
long-term viability of CI programmes. Provision should be concentrated in provider units 
located within easy access of the main population centres in the UK.  
 
In view of the size of the backlog of patients, there may be proposals to establish additional 
provider units. However, the incidence of new candidates, according to current criteria, is 
unlikely to sustain all centres that already exist. Purchasers should consider the merits of 
concentrating purchasing on a small number of expert providers who manage high-volume 
programmes.  
3.3.5 Criteria of Candidature 
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Cost-effectiveness will be optimised by selecting patients who are most likely to benefit, and 
least likely to develop complications or become non-users. The following criteria are 
relevant: 
 
Adults 
x Profound bilateral deafness of cochlear origin (average hearing level >95 dB); 
x Onset of profound deafness after acquiring spoken language; 
x No material benefit from acoustic hearing aids (average aided thresholds greater than 
about 60 dB(A)); 
x No material ability to understand speech using acoustic hearing aids (typically score less 
than 10% correct on a test requiring the identification of words in sentences without lip-
reading); 
x No morphological abnormality of the inner ear that would prevent the placement of 
electrodes close to surviving fibres of the auditory nerve; 
x Intellectually fit and mentally alert (no major psychological contra-indications; IQ>70); 
x Committed to their own health care and to the proposed treatment. 
 
Outcomes from adult implantation are highly variable, although positive for the great 
majority of patients individually. Statistically, the best outcomes tend to be achieved by 
patients with three characteristics: 
x Recent onset of profound deafness; 
x Some measurable residual hearing; 
x Proven skills in spoken language demonstrated by good lip-reading. 
 
Children with post-lingual deafness 
x The criteria listed above for adults apply here also. 
 
Children with pre-lingual deafness 
x Profound bilateral deafness of cochlear origin (average hearing level >95 dB); 
x No material benefit from acoustic hearing aids (average aided thresholds greater than 
about 60 dB(A); 
x Generally, age  2 years and older; CI may be indicated for some post-meningitics before     
the age of 2; 
x No morphological abnormality of the inner ear that would prevent the placement of 
electrodes close to surviving fibres of the auditory nerve; 
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x Strong commitment to treatment and to spoken language on the part of parents and 
teachers; 
x Implantation between the ages of 1 and 4 (i.e. before school entry) produces the best 
outcomes statistically. After the age of 10-13 years, outcomes are often poor and CI 
should not generally be encouraged; however, exceptional cases do arise, but should be 
justified on an individual basis. 
 
3.3.6 Competition Between Manufacturers 
 
Consortia of providers should be encouraged to negotiate favourable prices for bulk 
purchase of implant systems with established manufacturers. 
 
3.3.7 Purchasing Strategy 
 
To ensure that responsibilities are clearly located for:  
(a) justifying decisions to treat in relation to criteria of candidature;  
(b) furnishing audit and outcomes data; and  
(c) long-term maintenance of patients and devices. 
A complete service for an individual client should be purchased from a single provider. 
3ULPDU\ SURYLGHUV PD\ HQJDJH VHFRQGDU\ SURYLGHUV ORFDWHG FORVHU WR SDWLHQWV¶ KRPHV WR
provide aspects of pre-operative assessment and long-term maintenance. 
 
3.4 Emerging Trends 
 
3.4.1 Candidature 
 
In the USA, outcomes achieved by traditional candidates using 3rd-generation implant 
systems exceed those achieved by less impaired patients who obtain measurable, but very 
slight, benefit from hearing aids.5 As a result, criteria of candidature have been relaxed to 
LQFOXGHVRPHRIWKHVHµPDUJLQDOKHDULQJ-DLGXVHUV¶2QHDLPLVWRHQDEOHHDUO\SURYLVLRQWR
clients with progressive hearing losses. Further multi-centre research is needed in the UK to 
assess the cost-effectiveness of CI for this new group, and to specify revised protocols for 
assessing candidature. For the immediate future purchasers should continue to use 
the criteria of candidature as set out in this Guidance Note. 
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In the USA, cost-savings have been achieved in the management of patients by reducing in-
patient stays to one night and by minimising the amount of therapeutic rehabilitation 
provided to adult patients. Further research is needed to establish whether these changes 
are compatible with sustained cost-effectiveness. 
 
3.4.2 Developments in Technology 
 
There is no alternative technology on the horizon. Within the next two years, smaller implant 
SURFHVVRUV VW\OHG OLNH µEHKLQG-the-HDU¶ KHDULQJ DLGV ZLOO DSSHDU 2YHU WKH QH[W GHFDGH
totally implantable devices with advanced technical specifications may be developed, along 
with less advanced devices in which current levels of technology are consolidated at lower 
cost. Over the last decade, the real cost of implant hardware has fallen slightly, despite 
improvements in the technology. This trend should continue. 
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4. OPTIONS FOR PURCHASERS AND PROVIDERS 
 
7KHIROORZLQJRSWLRQVZHUHGLVFXVVHGGXULQJDQGDIWHUDVHPLQDUKHOGE\WKH7UHQW,QVWLWXWH¶V
Working Group on Acute Purchasing:  
 
Option 1  Purchasers should agree to fund only in the context of formal multi-centre 
  clinical studies. 
 
Option 2 Present arrangements should continue. Funding should be agreed for  
  provision: 
x In Cochlear Implantation centres; 
x Within agreed guidelines governing candidature; 
x With the assurance that the results of audit are reported. 
 
Option 3 Funding should be agreed for widespread provision, extending beyond  
  existing established provider units. 
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5. DISCUSSION AND CONCLUSION 
 
After discussion at the Trent seminar between representatives of purchasers and providers 
of Cochlear Implantation, it was concluded that: 
x There was strong evidence of the effectiveness of CI for adult and child clients meeting 
the criteria of candidature in this Guidance Note. (Those criteria are listed in the 
Summary Matrix overleaf). For this group of clients, Option 2 above should be adopted 
i.e., purchasing should continue as at present from established CI centres. 
x For non-traditional candidates, i.e. patients who gain measurable but slight benefit from 
acoustic hearing aids, Option 1 above should be adopted i.e., purchasing should be 
agreed only in the context of formal multi-centre clinical studies. 
x Prior to purchasing, evidence was required of: 
x levels of experience of the surgeon and other team members; 
x rationale for choice of devices; 
x number of  clients implanted at the centre to date; 
x incidence of major complications, including those leading to decisions to explant 
devices; 
x incidence of elective non-use of devices by implanted clients. 
x Purchasers should purchase the complete service for a client (assessment, implantation 
rehabilitation, and maintenance) from the same provider. 
x Purchasing consortia should be considered in view of the small number of clients for 
each individual purchaser. 
x Purchasers should consider the merits of concentrating purchasing on a small number of 
expert providers, who manage high volume programmes. 
x Provider consortia should be encouraged to negotiate more favourable prices for bulk 
purchases of implant systems with established manufacturers. 
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6. COCHLEAR IMPLANTATION: SUMMARY MATRIX 
 
CLIENT 
GROUP 
CRITERIA OF 
CANDIDATURE 
LIKELY UPPER LIMITS ON 
DEMAND IN A BENCH-MARK 
DISTRICT WITH A 
POPULATION OF 0.5 m 
OPPORTUNITIES TO 
IMPROVE COST-
EFFECTIVENESS 
AUDIT 
  BACKLOG ANNUAL 
RECURRENT 
DEMAND 
  
All clients x Profound bilateral 
deafness of cochlear 
origin (average hearing 
levels >95 dB). 
x No material benefit 
from acoustic hearing 
aids (average aided 
thresholds >60 db(A)). 
x No morphological 
abnormality of the 
inner ear that would 
prevent the placement 
of electrodes close to 
surviving fibres of the 
auditory nerve. 
  x Encourage 
concentration of 
services. 
x Ensure 
appropriately 
trained and 
experienced multi-
disciplinary team. 
x Ensure at least 12 
new patients 
implanted by centre 
per year. 
x Ensure provision of 
modern 
multichannel 
implant systems of 
proven 
effectiveness and 
reliability with which 
the team is familiar. 
x Encourage 
competition 
between 
manufacturers. 
 
Structure 
x Composition, 
training, and 
experience of 
team. 
x Rationale for 
choice of 
devices. 
 
Process 
x Number of 
patients being 
implanted 
annually. 
x Arrangements 
for long-term 
maintenance 
of patients and 
devices. 
 
Outcomes 
x Incidence of 
major 
complications, 
including those 
leading to 
decisions to 
explant 
devices. 
x Incidence of 
elective non-
use of devices 
by implanted 
clients. 
Adults and x Profound deafness 14 (range: 0.5 (range 0-2) Cost of treatment Outcomes 
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older 
children 
acquired after learning 
spoken language. 
x No material ability to 
understand speech 
using acoustic hearing 
aids (typically score 
less than 10% correct 
on a test requiring the 
identification of words 
in sentences without 
lip-reading). 
x Intellectually fit and 
mentally alert (no 
major psychological 
contra-indications; 
IQ>70).  
x Committed to their own 
health care and to the 
proposed treatment. 
11-20) (less 
patients 
already 
implanted). 
(i.e. 1 patient 
every 2 years 
with a likely 
range from no 
patients to 2 
patients per 
year). 
over 12 years: 
~£33,000 
Cost-utility: 
£13,300/QALY 
(assuming 26 years of 
use, with upgrades, and 
future costs and 
benefits discounted at 
6% per year) 
 
x Gain in 
accuracy of 
speech-
perception 
compared to 
pre-operative 
state. 
x Gain in quality-
of-life 
compared to 
pre-operative 
state. 
Younger 
children 
x Profound deafness 
acquired either before 
or after learning 
spoken language. 
x Strong commitment to 
treatment and to 
spoken language by 
family and teachers, 
and, if possible to 
assess, the client. 
x Preferably under the 
age of 5 years, 
allowing implantation 
before school entry. 
x After the age of 10-13 
years, outcomes are 
often poor and 
treatment should not 
be encouraged. 
10 (range: 7-
12) (less 
patients 
already 
implanted). 
2 (range: 0-4) 
(i.e. 2 patients 
per year with a 
likely range 
from no 
patients to 4 
patients per 
year). 
Cost of treatment 
over 12 years: 
~£53,000 
Outcomes 
x Observational 
measures of 
performance. 
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